Vitiligo in a patient receiving infliximab for refractory ulcerative colitis
Arab Journal of Gastroenterology. 2011; 12 (2): 109-111
en Inglés
| IMEMR
| ID: emr-123886
ABSTRACT
Infliximab is a chimerical monoclonal antibody that inhibits pro-inflammatory activity of tumour-necrosis factor alpha [TNF alpha] and it is the primary biological agent used in the treatment of moderate-to-severe ulcerative colitis [UC]. We report a case of vitiligo following infliximab administration in a patient with refractory UC. The case serves as a reminder of adverse cutaneous reactions induced by TNF alpha -antagonist therapy
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Vitíligo
/
Colitis Ulcerosa
/
Factor de Necrosis Tumoral alfa
Tipo de estudio:
Informe de Casos
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Arab J. Gastroenterol.
Año:
2011
Similares
MEDLINE
...
LILACS
LIS